Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Knopp Biosciences
Knopp Biosciences
Knopp’s oral asthma drug hits primary endpoint in phase 2
Fierce Biotech
Thu, 01/14/21 - 10:37 am
Knopp Biosciences
clinical trials
dexpramipexole
eosinophilic asthma
Knopp reports positive preclinical data for neonatal epilepsy drug candidate
Pharmaceutical Business Review
Mon, 05/27/19 - 11:45 pm
Knopp Biosciences
neonatal epilepsy
KB-3061
Knopp Biosciences' Dexpramipexole Meets Primary Endpoints in Phase 2 Trial Results in Hypereosinophilic Syndromes (HES)
CP Wire
Thu, 05/10/18 - 10:08 am
Knopp Biosciences
dexpramipexole
hypereosinophilic syndromes
Knopp Biosciences' Dexpramipexole Meets Primary Endpoints in Phase 2 Trial Results in Hypereosinophilic Syndromes (HES)
Thu, 05/10/18 - 10:09 am
Knopp Biosciences
dexpramipexole
hypereosinophilic syndromes